medical_technology

Stockholm – September 11, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.

Collaboration targets relapse prediction in atopic dermatitis patients

SciBase and Castle Biosciences entered a collaboration and license agreement in 2025. The first joint study under that agreement aims to predict relapses in atopic dermatitis and is currently underway, with the new order funding both faster progression of that trial and groundwork for a follow-up study.

Boston – September 08, 2026 -- HoneyNaps has developed a wireless polysomnography (PSG) system that replaces more than 24 wired sensors with four compact skin patches, combining patch-based sensing with AI-driven sleep analysis.

System consolidates dozens of wired sensors into four wearable patches

Conventional PSG, the standard diagnostic test for sleep disorders such as sleep apnea, typically requires patients to spend a night in a hospital wired to more than 24 sensors placed across the face, chest, abdomen and legs. HoneyNaps' Wireless PSG system instead uses a Head Sensor, Chest Sensor, Body Sensor and Leg Sensor to capture EEG, EOG, ECG, EMG, respiratory airflow, SpO2, body position and physical activity without cables.

Austin – September 07, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first facility in the United States to enroll in a clinical trial evaluating a next-generation mapping and pulsed field ablation (PFA) system for patients with paroxysmal and persistent atrial fibrillation.

TCAI performs first procedure under global study leadership

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, conducted the first procedure using the new catheter system. The trial is designed to assess the safety and efficacy of the technology across both forms of atrial fibrillation, the most common cardiac arrhythmia, which affects millions of patients worldwide.

Austin, Texas – September 7, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.

Frankfurt (Oder), Germany -- Klinikum Frankfurt (Oder) opened a new hybrid operating room on Aug. 31, 2026, backed by roughly 6 million euros in investment, RHÖN-KLINIKUM AG announced. The facility, one of five hospitals in the Rhön-Klinikum network, will serve as the primary site for vascular surgery and cardiology teams treating complex vascular and cardiac cases across eastern Brandenburg. Hospital managing director Christian Petersen and chief medical officer Prof. Richter-Ehrenstein presented the room as a step toward offering high-end interventional procedures rarely available outside specialized centers.